156 related articles for article (PubMed ID: 37610374)
1. Prevalence and spectrum of cancer predisposition germline mutations in young patients with the common late-onset cancers.
Hao S; Zhao X; Fan Y; Liu Z; Zhang X; Li W; Yuan H; Zhang J; Zhang Y; Ma T; Tao H
Cancer Med; 2023 Sep; 12(17):18394-18404. PubMed ID: 37610374
[TBL] [Abstract][Full Text] [Related]
2. Prevalence and clinical implications of germline mutations among Jordanian patients with ovarian cancer. The Jordanian exploratory cancer genetics (Jo-ECAG) ovarian study.
Abdel-Razeq H; Al-Azzam K; Elemian S; Abu-Fares H; Abu Sheikha A; Bani Hani H; Bater R; Sharaf B; Heald B; Esplin ED; Nielsen SM; Alkyam M; Abujamous L; Al-Attary A
Mol Genet Genomic Med; 2023 Apr; 11(4):e2125. PubMed ID: 36537080
[TBL] [Abstract][Full Text] [Related]
3. Molecular characteristics of breast tumors in patients screened for germline predisposition from a population-based observational study.
Nacer DF; Vallon-Christersson J; Nordborg N; Ehrencrona H; Kvist A; Borg Å; Staaf J
Genome Med; 2023 Apr; 15(1):25. PubMed ID: 37060015
[TBL] [Abstract][Full Text] [Related]
4. Prevalence and spectrum of pathogenic germline variants in intestinal and pancreatobiliary type of ampullary cancer.
Kumari N; Singh RK; Mishra SK; L R; Mohindra S; Krishnani N
Pathol Res Pract; 2021 Jan; 217():153309. PubMed ID: 33341547
[TBL] [Abstract][Full Text] [Related]
5. Germline mutations of renal cancer predisposition genes and clinical relevance in Chinese patients with sporadic, early-onset disease.
Wu J; Wang H; Ricketts CJ; Yang Y; Merino MJ; Zhang H; Shi G; Gan H; Linehan WM; Zhu Y; Ye D
Cancer; 2019 Apr; 125(7):1060-1069. PubMed ID: 30548481
[TBL] [Abstract][Full Text] [Related]
6. Unexpected actionable genetic variants revealed by multigene panel testing of patients with uterine cancer.
Heald B; Mokhtary S; Nielsen SM; Rojahn S; Yang S; Michalski ST; Esplin ED
Gynecol Oncol; 2022 Aug; 166(2):344-350. PubMed ID: 35691755
[TBL] [Abstract][Full Text] [Related]
7. Pathogenic Germline Variants in BRCA1/2 and p53 Identified by Real-world Comprehensive Cancer Genome Profiling Tests in Asian Patients.
Satake T; Kondo S; Tanabe N; Mizuno T; Katsuya Y; Sato J; Koyama T; Yoshida T; Hirata M; Yamamoto N
Cancer Res Commun; 2023 Nov; 3(11):2302-2311. PubMed ID: 37916805
[TBL] [Abstract][Full Text] [Related]
8. Rate of Pathogenic Germline Variants in Patients With Lung Cancer.
Sorscher S; LoPiccolo J; Heald B; Chen E; Bristow SL; Michalski ST; Nielsen SM; Lacoste A; Keyder E; Lee H; Nussbaum RL; Martins R; Esplin ED
JCO Precis Oncol; 2023 Sep; 7():e2300190. PubMed ID: 37992258
[TBL] [Abstract][Full Text] [Related]
9. Yield and Utility of Germline Testing Following Tumor Sequencing in Patients With Cancer.
Lincoln SE; Nussbaum RL; Kurian AW; Nielsen SM; Das K; Michalski S; Yang S; Ngo N; Blanco A; Esplin ED
JAMA Netw Open; 2020 Oct; 3(10):e2019452. PubMed ID: 33026450
[TBL] [Abstract][Full Text] [Related]
10. Addition of Germline Testing to Tumor-Only Sequencing Improves Detection of Pathogenic Germline Variants in Men With Advanced Prostate Cancer.
Berchuck JE; Boiarsky D; Silver R; Sunkara R; McClure HM; Tsai HK; Siegmund S; Tewari AK; Nowak JA; Lindeman NI; Rana HQ; Choudhury AD; Pomerantz MM; Freedman ML; Van Allen EM; Taplin ME
JCO Precis Oncol; 2022 Aug; 6():e2200329. PubMed ID: 36103646
[TBL] [Abstract][Full Text] [Related]
11. Optimization of prediction methods for risk assessment of pathogenic germline variants in the Japanese population.
Senda N; Kawaguchi-Sakita N; Kawashima M; Inagaki-Kawata Y; Yoshida K; Takada M; Kataoka M; Torii M; Nishimura T; Kawaguchi K; Suzuki E; Kataoka Y; Matsumoto Y; Yoshibayashi H; Yamagami K; Tsuyuki S; Takahara S; Yamauchi A; Shinkura N; Kato H; Moriguchi Y; Okamura R; Kan N; Suwa H; Sakata S; Mashima S; Yotsumoto F; Tachibana T; Tanaka M; Togashi K; Haga H; Yamada T; Kosugi S; Inamoto T; Sugimoto M; Ogawa S; Toi M
Cancer Sci; 2021 Aug; 112(8):3338-3348. PubMed ID: 34036661
[TBL] [Abstract][Full Text] [Related]
12. Risk of Syndrome-Associated Cancers Among First-Degree Relatives of Patients With Pancreatic Ductal Adenocarcinoma With Pathogenic or Likely Pathogenic Germline Variants.
Chen X; Meyer MA; Kemppainen JL; Horibe M; Chandra S; Majumder S; Petersen GM; Rabe KG
JAMA Oncol; 2023 Jul; 9(7):955-961. PubMed ID: 37200008
[TBL] [Abstract][Full Text] [Related]
13. Germline Mutations for Novel Candidate Predisposition Genes in Sporadic Schwannomatosis.
Min BJ; Kang YK; Chung YG; Seo ME; Chang KB; Joo MW
Clin Orthop Relat Res; 2020 Nov; 478(11):2442-2450. PubMed ID: 32281771
[TBL] [Abstract][Full Text] [Related]
14. Prospective study of germline genetic testing in incident cases of pancreatic adenocarcinoma.
Brand R; Borazanci E; Speare V; Dudley B; Karloski E; Peters MLB; Stobie L; Bahary N; Zeh H; Zureikat A; Hogg M; Lee K; Tsung A; Rhee J; Ohr J; Sun W; Lee J; Moser AJ; DeLeonardis K; Krejdovsky J; Dalton E; LaDuca H; Dolinsky J; Colvin A; Lim C; Black MH; Tung N
Cancer; 2018 Sep; 124(17):3520-3527. PubMed ID: 30067863
[TBL] [Abstract][Full Text] [Related]
15. Performance of clinical risk scores and prediction models to identify pathogenic germline variants in patients with advanced prostate cancer.
Rebhan K; Stelzer PD; Pradere B; Rajwa P; Kramer G; Hofmann B; Resch I; Yurdakul O; Laccone FA; Bujalkova MG; Smogavec M; Tan YY; Ristl R; Shariat SF; Egger G; Hassler MR
World J Urol; 2023 Aug; 41(8):2091-2097. PubMed ID: 37528288
[TBL] [Abstract][Full Text] [Related]
16. Germline Genetic Testing in Unselected Squamous and Non-Squamous Head and Neck Cancers.
Brake DA; Idler BM; Kunze KL; Golafshar MA; Heald B; Young S; Klint M; Barrus K; Esplin ED; Nussbaum RL; Samadder NJ; Hinni ML; Chang BA
Laryngoscope; 2023 Dec; 133(12):3378-3388. PubMed ID: 37132629
[TBL] [Abstract][Full Text] [Related]
17. Genetic insights: High germline variant rate in an indigenous African cohort with early-onset colorectal cancer.
Yildiz S; Musarurwa TN; Algar U; Chambuso R; Rebello G; Goldberg PA; Ramesar R
Front Oncol; 2023; 13():1253867. PubMed ID: 37965459
[TBL] [Abstract][Full Text] [Related]
18. Prospective Statewide Study of Universal Screening for Hereditary Colorectal Cancer: The Ohio Colorectal Cancer Prevention Initiative.
Pearlman R; Frankel WL; Swanson BJ; Jones D; Zhao W; Yilmaz A; Miller K; Bacher J; Bigley C; Nelsen L; Goodfellow PJ; Goldberg RM; Paskett E; Shields PG; Freudenheim JL; Stanich PP; Lattimer I; Arnold M; Prior TW; Haut M; Kalady MF; Heald B; Paquette I; Draper DJ; Brell JM; Mahesh S; Weeman K; Bastola S; Zangmeister J; Gowda A; Kencana F; Malcolm A; Liu Y; Cole S; Bane C; Li C; Rehmus E; Pritchard CC; Shirts BH; Jacobson A; Cummings SA; de la Chapelle A; Hampel H
JCO Precis Oncol; 2021; 5():. PubMed ID: 34250417
[TBL] [Abstract][Full Text] [Related]
19. Targeted gene panels identify a high frequency of pathogenic germline variants in patients diagnosed with a hematological malignancy and at least one other independent cancer.
Singhal D; Hahn CN; Feurstein S; Wee LYA; Moma L; Kutyna MM; Chhetri R; Eshraghi L; Schreiber AW; Feng J; Wang PP; Babic M; Parker WT; Gao S; Moore S; Das S; Thomas D; Pattnaik S; Brown AL; D'Andrea RJ; Poplawski NK; Thomas D; Scott HS; Godley LA; Hiwase DK
Leukemia; 2021 Nov; 35(11):3245-3256. PubMed ID: 33850299
[TBL] [Abstract][Full Text] [Related]
20. Family Matters: Germline Testing in Thoracic Cancers.
Hathaway F; Martins R; Sorscher S; Bzura A; Dudbridge F; Fennell DA
Am Soc Clin Oncol Educ Book; 2023 May; 43():e389956. PubMed ID: 37167572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
